PMID- 25920090
OWN - NLM
STAT- MEDLINE
DCOM- 20160208
LR  - 20220410
IS  - 1600-0641 (Electronic)
IS  - 0168-8278 (Linking)
VI  - 62
IP  - 1 Suppl
DP  - 2015 Apr
TI  - NAFLD: a multisystem disease.
PG  - S47-64
LID - S0168-8278(14)00933-7 [pii]
LID - 10.1016/j.jhep.2014.12.012 [doi]
AB  - Non-alcoholic fatty liver disease (NAFLD) is the most common cause of chronic 
      liver disease in Western countries that is predicted to become also the most 
      frequent indication for liver transplantation by 2030. Over the last decade, it 
      has been shown that the clinical burden of NAFLD is not only confined to 
      liver-related morbidity and mortality, but there is now growing evidence that 
      NAFLD is a multisystem disease, affecting extra-hepatic organs and regulatory 
      pathways. For example, NAFLD increases risk of type 2 diabetes mellitus (T2DM), 
      cardiovascular (CVD) and cardiac diseases, and chronic kidney disease (CKD). 
      Although the primary liver pathology in NAFLD affects hepatic structure and 
      function to cause morbidity and mortality from cirrhosis, liver failure and 
      hepatocellular carcinoma, the majority of deaths among NAFLD patients are 
      attributable to CVD. This narrative review focuses on the rapidly expanding body 
      of clinical evidence that supports the concept of NAFLD as a multisystem disease. 
      The review discusses the factors involved in the progression of liver disease in 
      NAFLD and the factors linking NAFLD with other extra-hepatic chronic diseases, 
      such as T2DM, CVD, cardiac diseases and CKD. The review will not discuss NAFLD 
      treatments as these are discussed elsewhere in this issue of the Journal. For 
      this review, PubMed was searched for articles using the keywords "non-alcoholic 
      fatty liver disease" or "fatty liver" combined with "diabetes", "cardiovascular 
      (or cardiac) disease", "cardiovascular mortality" or "chronic kidney disease" 
      between 1990 and 2014. Articles published in languages other than English were 
      excluded.
CI  - Copyright (c) 2014 European Association for the Study of the Liver. Published by 
      Elsevier B.V. All rights reserved.
FAU - Byrne, Christopher D
AU  - Byrne CD
AD  - Nutrition and Metabolism, Faculty of Medicine, University of Southampton, 
      Southampton, UK; Southampton National Institute for Health Research, Biomedical 
      Research Centre, University Hospital Southampton, UK. Electronic address: 
      cdtb@soton.ac.uk.
FAU - Targher, Giovanni
AU  - Targher G
AD  - Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, 
      University and Azienda Ospedaliera Universitaria Integrata of Verona, Verona, 
      Italy.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - Netherlands
TA  - J Hepatol
JT  - Journal of hepatology
JID - 8503886
SB  - IM
MH  - Cardiovascular Diseases/etiology
MH  - Diabetes Mellitus, Type 2/etiology
MH  - Humans
MH  - Non-alcoholic Fatty Liver Disease/complications/diagnosis/*therapy
OTO - NOTNLM
OT  - Cardiac arrhythmias
OT  - Cardiac disease
OT  - Cardiovascular disease
OT  - Chronic kidney disease
OT  - Hepatocellular carcinoma
OT  - Insulin resistance
OT  - Non-alcoholic fatty liver disease
OT  - Type 2 diabetes
EDAT- 2015/04/29 06:00
MHDA- 2016/02/09 06:00
CRDT- 2015/04/29 06:00
PHST- 2014/09/05 00:00 [received]
PHST- 2014/11/06 00:00 [revised]
PHST- 2014/12/09 00:00 [accepted]
PHST- 2015/04/29 06:00 [entrez]
PHST- 2015/04/29 06:00 [pubmed]
PHST- 2016/02/09 06:00 [medline]
AID - S0168-8278(14)00933-7 [pii]
AID - 10.1016/j.jhep.2014.12.012 [doi]
PST - ppublish
SO  - J Hepatol. 2015 Apr;62(1 Suppl):S47-64. doi: 10.1016/j.jhep.2014.12.012.